clinical trial · NCT05285904
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Multiple SclerosisOfatumumab
brief summary
This is a multi-center, observational study carried out in Switzerland that aims to describe the effects of Ofatumumab in a setting of routine medical care.
started
May 12, 2022
primary completion
Feb 4, 2026
completion
Feb 4, 2026
last updated
Apr 14, 2026
detailed description
This non-interventional study will observe the effect of Ofatumumab treatment compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS-COMB157G3301) in MS patients in a real-world setting in Switzerland over an observational period of 12 month.
official title
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol